Comparative Pharmacology
Head-to-head clinical analysis: KESIMPTA versus LEQEMBI IQLIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KESIMPTA versus LEQEMBI IQLIK.
KESIMPTA vs LEQEMBI IQLIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KESIMPTA (ofatumumab) is a fully human anti-CD20 monoclonal antibody that selectively binds to the CD20 antigen on B lymphocytes, leading to B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This results in depletion of circulating B cells, reducing inflammatory demyelination in multiple sclerosis.
Monoclonal antibody targeting aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.
20 mg administered subcutaneously once monthly after a loading dose of 20 mg on Days 0, 7, and 14.
Lecanemab (LEQEMBI IQLIK) for Alzheimer disease: 10 mg/kg IV infusion every 2 weeks, diluted in 250 mL saline, administered over approximately 1 hour. Initiate with 1 mg/kg IV on day 0 and 3 mg/kg IV on day 14 for titration, then 10 mg/kg IV every 2 weeks.
None Documented
None Documented
16 days (range 13–20 days) with linear pharmacokinetics; supports every 4-week dosing.
Terminal half-life approximately 24.6 days (range 23-27 days) in patients with Alzheimer's disease; supports monthly intravenous dosing.
Primarily degraded into small peptides and amino acids; not excreted renally or fecally as intact drug. Elimination pathways not fully characterized due to monoclonal antibody catabolism.
Primarily proteolytic catabolism to amino acids; renal elimination of intact drug is negligible (<1%). Biliary/fecal excretion is not a major route.
Category C
Category C
Monoclonal Antibody, Anti-CD20
Monoclonal Antibody